Renal Cell Carcinoma

The FDA granted priority review to pembrolizumab as adjuvant therapy for certain patients with renal cell carcinoma, according to the agent’s manufacturer.

Pembrolizumab plus axitinib continued to exhibit superior efficacy to sunitinib as first-line therapy for advanced clear cell renal cell carcinoma, according to long-term follow-up of the randomized phase 3 KEYNOTE-426 trial.

Adjuvant pembrolizumab appeared associated with a significant and clinically meaningful improvement in DFS vs. placebo among patients with clear cell renal carcinoma, according to results of the KEYNOTE-564 trial.

About 4% of patients with advanced renal cell carcinoma had asymptomatic brain metastases, according to results of a retrospective multi-institutional cohort study published in Journal of the National Comprehensive Cancer Network.

Adjuvant pembrolizumab prolonged DFS compared with placebo for patients with renal cell carcinoma who underwent nephrectomy with or without resection of metastatic lesions, according to the agent’s manufacturer.

The FDA granted priority review to belzutifan for treatment of certain patients with renal cell carcinoma.

The FDA approved tivozanib for treatment of adults with relapsed or refractory advanced renal cell carcinoma.

Pembrolizumab monotherapy showed promising antitumor activity and durable response rates as initial treatment for both clear cell and non-clear cell advanced renal cell carcinoma.

Cabozantinib conferred a significant and meaningful extension of PFS compared with sunitinib in metastatic papillary renal cell carcinoma, according to results of a phase 2 randomized trial presented at Genitourinary Cancers Symposium.

The combination of lenvatinib and pembrolizumab significantly prolonged OS and PFS compared with sunitinib among previously untreated patients with advanced renal cell carcinoma, according to results of the phase 3 CLEAR trial.